At 4.9% CAGR, the Europe Human Papillomavirus (HPV) Vaccine Market is  projected to be worth US$ 1,598.81 million by 2028, says The Insight  Partners      

According to Business Market Insights’ research, the Europe human papillomavirus (HPV) vaccine market was valued at US$ 1,202.66 million in 2022 and is expected to reach US$ 1,598.81 million by 2028, registering an annual growth rate of 4.9%  from 2022 to 2028. The growing number of HPV awareness programs and increase in prevalence of HPV associated diseases are the critical factors attributed to the market expansion.  

The increase in programs for HPV awareness is one of the effective strategies to increase the vaccination uptake and eliminate HPV-associated cancers. Additionally, in collaboration with computer scientists, HPV-related Epidemiological Research Unit, Norway, developed an innovative approach to communicate the importance of cervical cancer prevention to girls, women, boys, and men of different ages. Therefore, the market in developing countries is likely to show high growth potential over the next few years.

On the contrary, high cost of HPV vaccines hurdles the growth of Europe human papillomavirus (HPV) vaccine market.   

Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 59.4% market share in 2022, amassing US$ 714.89 million. It is projected to garner US$ 951.43 million by 2028 to expand at 4.9% CAGR during 2022–2028.   

Based on dosage, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 63.9% market share in 2022, amassing US$  768.35 million. It is projected to garner US$ 1,009.64 million by 2028 to expand at 4.7% CAGR during 2022–2028.     

Based on age, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 75.1% market share in 2022, amassing US$ 903.22 million. It is projected to garner US$ 1,191.15 million by 2028 to expand at 4.7% CAGR during 2022–2028.      

Based on application, the Europe human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 82.6% market share in 2022, amassing US$ 992.96 million. It is projected to garner US$  1,334.42 million by 2028 to expand at 5.0% CAGR during 2022–2028.              

Based on end user, the Europe human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 39.1% market share in 2022, amassing US$ 469.64 million. It is projected to garner US$ 619.06 million by 2028 to expand at 4.7% CAGR during 2022–2028.               

Based on country, the Europe human papillomavirus (HPV) vaccine market has been categorized into the U.K., Germany, France, Italy, Spain, Russia, Belarus, and rest of Europe. Our regional analysis states that Germany captured 29.8% market share in 2022. It was assessed at US$ 358.51 million in 2022 and is likely to hit US$ 468.93 million by 2028, exhibiting a CAGR of 4.6% during the forecast period.      

Key players dominating the Europe human papillomavirus (HPV) vaccine market are 2A Pharma; ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. among others.        

• In Nov 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma Inc.

• In Feb 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com